Author: Bill Snyder
“Ultra-potent” antibody against COVID-19 variants isolated at VUMC
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
VUMC team to test personalized acute heart failure treatment
Sep. 16, 2021—Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure.
Chung receives early investigator award from ASCPT
Sep. 16, 2021—Vanderbilt's Cecilia Chung, MD, MPH, has received the 2022 Leon I. Goldberg Early Investigator Award from the American Society of Clinical Pharmacology and Therapeutics (ASCPT).
‘Pre-conditioning’ restores immune tolerance
Sep. 16, 2021—A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.
VUMC antibodies help neutralize two deadly viruses: study
Sep. 8, 2021—Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.
Discovery offers insight for development of cancer therapies targeting mutant p53
Sep. 2, 2021—Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study
Aug. 20, 2021—A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
Potential protection from atherosclerosis
Aug. 19, 2021—Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.
Team isolates antibodies that target alphaviruses
Aug. 19, 2021—A multi-institutional team led by researchers at Vanderbilt University Medical Center has isolated monoclonal antibodies that in laboratory and animal studies prevented infection by alphaviruses, including the often-lethal Eastern equine encephalitis virus (EEEV).
Collaborative helping Midstate nursing homes control COVID-19
Aug. 18, 2021—Vanderbilt University Medical Center (VUMC) has received a two-year, $1.2 million award from the Tennessee Department of Health and Centers for Medicare and Medicaid Services to provide tailored education and coaching to 75 Middle Tennessee nursing homes focused on infection control, quality improvement and other pandemic-related challenges.
Vega selected as 2021 Vanderbilt Prize Student Scholar
Aug. 11, 2021—Paige Vega, a PhD student in the Department of Cell and Developmental Biology at Vanderbilt University, has been selected as the 2021 Vanderbilt Prize Student Scholar.
Shared antibodies may push COVID-19 variants: VUMC study
Aug. 10, 2021—Researchers at Vanderbilt University Medical Center have found that people recovering from COVID-19 and those vaccinated against the causative virus, SARS-CoV-2, produce identical clones, or groups, of antibody-producing white blood cells.
